
From: Trials <Trials@USPTO.GOV>
Sent: Friday, June 7, 2024 10:23 AM
To: John Wittenzellner; Trials
Cc: Medtronic WSL Counsel; sfuller@ghiplaw.com; litigation@ghiplaw.com; rvazquez@sinergialaw.com
Subject: RE: IPR2024-00713 | Request for Leave to File Joint Motion to Terminate IPR

[EXTERNAL EMAIL]

Counsel,

The parties are authorized to file a joint motion to terminate the proceeding in IPR2024-00713. Any agreement between the parties made in connection with the termination of the proceeding must be in writing and a true copy must be filed with the Board. 37 C.F.R. § 42.74(b). The parties are also authorized to file a joint request to treat the settlement agreement as business confidential. 37 C.F.R. § 42.74(c). A conference call is not necessary.

Regards,

Esther Goldschlager
Supervisory Paralegal Specialist
Patent Trial & Appeal Board
U.S. Patent & Trademark Office

From: John Wittenzellner <johnw@wsltrial.com>
Sent: Wednesday, June 5, 2024 10:26 AM
To: Trials <Trials@USPTO.GOV>
Cc: Medtronic WSL Counsel <MedtronicWSLCounsel@wsltrial.com>; sfuller@ghiplaw.com; litigation@ghiplaw.com; rvazquez@sinergialaw.com
Subject: IPR2024-00713 | Request for Leave to File Joint Motion to Terminate IPR

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

To the Board:

I represent Petitioner in IPR2024-00713. Petitioner and Patent Owner (cc'd here) seek leave to file a joint motion to terminate this IPR in view of a settlement agreement that resolves all disputes between the parties. The settlement agreement is confidential, so the parties also seek leave to file a request to treat the settlement agreement as confidential.

The parties are available this week for a conference call if one is necessary.

Best regards,
John

John Wittenzellner
Williams Simons & Landis PLLC
1735 Market Street, Suite A #453

Philadelphia, PA 19103
Direct: 512.543.1373



CONFIDENTIALITY NOTICE: The information in this email may be confidential and/or privileged. This email is intended to be reviewed by only the individual or organization named above. If you are not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any review, dissemination or copying of this email and any attachments or the information contained herein is prohibited. If you have received this email in error, please immediately notify the sender by return email and delete this email from your system. Thank You.